Transasia Bio-Medicals Acquires Calbiotech Group
By LabMedica International staff writers Posted on 01 May 2017 |
Image: The Calbiotech team (Photo courtesy of Calbiotech Group).
Transasia Bio-Medicals Ltd., an in-vitro diagnostic company, has acquired immunoassay developer and manufacturer Calbiotech Group of Companies through its subsidiary Erba Mannheim.
The Transasia- Erba Group offers a comprehensive portfolio in different specialties including clinical chemistry, immunology, hematology, hemostasis, critical care, electrophoresis, urinalysis, diabetes monitoring, autoimmune & infectious disease monitoring, molecular diagnostics and microbiology. Calbiotech is a worldwide leader in immunoassay development and manufacturing and was the first company to introduce immunoassay kits in the US to detect antibodies against Zika virus in human blood. The acquisition of Calbiotech has strengthened the Transasia-Erba Group’s foray into ELISA and CLIA assays for human and animal research, including specific assays for autoimmune disorders, cancer and infectious diseases.
“Calbiotech Inc. and Dr. Noori Barka have developed an excellent range of immunoassay products that will complement our growing range of diagnostic products. Globally, the immunology segment of the IVD industry is valued at around USD 15 billion,” said Mr. Suresh Vazirani, Chairman & Managing Director, Transasia-Erba Group. “Calbiotech’s expertise in immunoassay will allow us to strengthen our position in this high growth market and integrate their strong R&D program to further enhance the product development strategy of the Transasia- Erba Group.”
The Transasia- Erba Group offers a comprehensive portfolio in different specialties including clinical chemistry, immunology, hematology, hemostasis, critical care, electrophoresis, urinalysis, diabetes monitoring, autoimmune & infectious disease monitoring, molecular diagnostics and microbiology. Calbiotech is a worldwide leader in immunoassay development and manufacturing and was the first company to introduce immunoassay kits in the US to detect antibodies against Zika virus in human blood. The acquisition of Calbiotech has strengthened the Transasia-Erba Group’s foray into ELISA and CLIA assays for human and animal research, including specific assays for autoimmune disorders, cancer and infectious diseases.
“Calbiotech Inc. and Dr. Noori Barka have developed an excellent range of immunoassay products that will complement our growing range of diagnostic products. Globally, the immunology segment of the IVD industry is valued at around USD 15 billion,” said Mr. Suresh Vazirani, Chairman & Managing Director, Transasia-Erba Group. “Calbiotech’s expertise in immunoassay will allow us to strengthen our position in this high growth market and integrate their strong R&D program to further enhance the product development strategy of the Transasia- Erba Group.”
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus